Coding

Part:BBa_K4165012

Designed by: Esraa Elmligy   Group: iGEM22_CU_Egypt   (2022-09-29)
Revision as of 18:10, 10 October 2022 by Esraa Elmligy (Talk | contribs) (Dry Lab Characterization)


Seed peptide (GGVVIA)

This part encodes Amyloid 𝛽 seed (37-42) which has the ability to bind to A𝛽 plaques inside the brain.

Usage and Biology

A short peptide derived from amyloid beta oligomers (A𝛽 37-42), which is proven to bind amyloid beta plaques inside the brain and stop plaque formation. This peptide showed no cytotoxicity when tested inside hippocampal cell lines, so it will be suitable to use as the targeting domain for A𝛽 plaques inside our system.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Dry Lab Characterization

Modeling


                                      Figure 1. RCSB model of seed peptide (37-42) 


Docking

ΔG = -168.522

                         Figure 1. Docked structure of seed peptide against whole tau aggregates


ΔG = -4.301

                         Figure 1. Docked structure of seed peptide against PHF of fibrils


ΔG = -2.769

                         Figure 1. Docked structure of seed peptide against PHF* of fibrils

ΔG = -44.19

                         Figure 1. Docked structure of seed peptide against amyloid beta

References

1. Fradinger, E. A., Monien, B. H., Urbanc, B., Lomakin, A., Tan, M., Li, H., Spring, S. M., Condron, M. M., Cruz, L., Xie, W., Benedek, G. B., & Bitan, G. (2008). C-terminal peptides coassemble into Aβ42 oligomers and protect neurons against Aβ42-induced neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 105(37), 14175-14180. https://doi.org/10.1073/pnas.0807163105

[edit]
Categories
Parameters
None